Badreddin Edris - 05 Jan 2023 Form 4 Insider Report for SpringWorks Therapeutics, Inc. (SWTX)

Role
Chief Operating Officer
Signature
/s/ Francis I. Perier, Jr. as Attorney-in Fact
Issuer symbol
SWTX
Transactions as of
05 Jan 2023
Net transactions value
-$91,532
Form type
4
Filing time
09 Jan 2023, 16:01:19 UTC
Previous filing
28 Jun 2022
Next filing
14 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SWTX Common Stock Award +33,994 +16% 242,032 05 Jan 2023 Direct F1
transaction SWTX Common Stock Tax liability $91,532 -3,326 -1.4% $27.52 238,706 06 Jan 2023 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SWTX Stock Option (Right to Buy) Award $0 +105,000 $0.000000 105,000 05 Jan 2023 Common Stock 105,000 $27.64 Direct F4
transaction SWTX Stock Option (Right to Buy) Award $0 +135,000 $0.000000 135,000 05 Jan 2023 Common Stock 135,000 $27.64 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction represents a grant of restricted stock units ("RSUs"). The RSUs shall vest as follows: thirty three percent (33%) to vest on January 5, 2024, another thirty three percent (33%) to vest on January 5, 2025 and the remaining thirty four percent (34%) to vest on January 5, 2026, such that the restricted stock awards are fully vested on January 5, 2026.
F2 Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person.
F3 Reflects a correction to the total number of securities beneficially owned, previously reported on a Form 4/A filed on January 14, 2022.
F4 This option shall vest in 48 equal monthly installments subject to continued service to the Issuer by the Reporting Person.
F5 Twenty-five percent (25%) of this option shall vest and become exercisable on January 5, 2024, with the remaining seventy-five percent (75%) to vest in thirty-six (36) equal monthly installments thereafter subject to continued service to the Issuer by the Reporting Person.